{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-09-18T15:31:45.618Z","profile":{"slug":"aod-9604","name":"AOD-9604","aliases":["AOD9604","Anti-Obesity Drug 9604","hGH fragment 177-191 analog"],"category":"Growth-hormone fragment analog"},"synthesis":{"mechanism":"AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone and was developed to investigate lipolytic and anti-obesity effects while attempting to avoid the broader growth-promoting actions of full-length growth hormone.","evidence":"Direct clinical development included obesity studies, but the available program did not establish a regulator-approved weight-loss indication. The modern literature is limited and includes preclinical work, reviews, analytical detection, regulatory, and anti-doping context.","safety":"Published exposure is insufficient to establish long-term cardiovascular, metabolic, endocrine, immunogenic, reproductive, or malignancy-related safety. Product identity and quality are additional concerns outside regulated clinical manufacturing.","observationalBoundary":"This profile separates AOD-9604-specific studies from growth-hormone-fragment biology and regulatory or anti-doping context. Related-fragment evidence is not presented as direct proof of clinical benefit.","openQuestions":"Can a composition-confirmed AOD-9604 product demonstrate clinically meaningful efficacy, durable outcomes, target engagement, and acceptable long-term safety in independently replicated controlled trials?"},"completion":{"version":"wpf-profile-v1.0","complete":true,"checks":[{"key":"overview","passed":true,"actual":251,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":274,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":247,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":204,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":204,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":true,"actual":25,"required":25,"severity":"blocking"},{"key":"reviewed_sources","passed":true,"actual":25,"required":1,"severity":"blocking"},{"key":"chemistry","passed":true,"actual":true,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":true,"actual":2,"required":2,"severity":"blocking"},{"key":"claims","passed":true,"actual":25,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":[]},"chemistry":{"id":"7a4dbebb7302aed117e2c3d801b2fa17","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","molecularFormula":null,"molecularWeight":null,"aminoAcidSequence":"YLRIVQCRSVEGSCGF","smiles":null,"inchi":null,"inchikey":null,"structureImageUrl":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},"evidence":[{"id":"d977ce4ff2c8a161d425f07ff4c98d2b","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Drugs@FDA: FDA-Approved Drugs database","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","evidenceTier":"insufficient","summary":"Official FDA database used to verify whether an AOD-9604 drug product or indication has received FDA approval.","authors":"U.S. Food and Drug Administration","publishingOrg":null,"publicationYear":2026,"doi":null,"pubmedId":null,"jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes regulatory evidence concerning Drugs@FDA: FDA-Approved Drugs database","supportNature":"contextualizes","qualification":"Absence of an approved product does not itself establish efficacy or safety; database status can change.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"url:https://www.accessdata.fda.gov/scripts/cder/daf/","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"U.S. FDA","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"regulatory","extractionPayload":{"limitations":["Absence of an approved product does not itself establish efficacy or safety; database status can change."],"studyDesign":"Official regulatory database","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B+","score":84,"version":"WPF-ESR-1.0","dimensions":{"authority":98,"reporting":88,"directness":90,"replication":65,"designAndBias":80,"populationRelevance":75},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"regulatory_context"},"provenancePayload":{"doi":null,"pmid":null,"retrievedFrom":"U.S. FDA"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"ae59a8f4e28521c918339e89f58ed4a6","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42328738/","evidenceTier":"laboratory","summary":"Stability studies showed that all compounds were stable (variation lower than 15%) for at least two months at -20 C in all the blood matrices considered. At 4 and 22 C, alexamorelin, AOD9604, buserelin, hGH 176-191, kisspeptin-10 and LHRH were extensively degraded after …","authors":"Mazzarino M, Colpaert T, Deventer K, Van Eenoo P.","publishingOrg":null,"publicationYear":2026,"doi":"10.1039/d6an00455e","pubmedId":"42328738","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1039/d6an00455e","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1039/d6an00455e","pmid":"42328738","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"1ff7574acaeab39beb9ac62b31864cb6","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41966639/","evidenceTier":"phase_1_2","summary":"Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-129 …","authors":"Mendias CL, Awan TM.","publishingOrg":null,"publicationYear":2026,"doi":"10.1007/s40279-026-02437-0","pubmedId":"41966639","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes human_interventional evidence concerning Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.","supportNature":"contextualizes","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s40279-026-02437-0","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"human_interventional","extractionPayload":{"limitations":["Compound-specific human evidence remains limited in size, duration, outcomes, or replication."],"studyDesign":"Human interventional or clinical study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B","score":74,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":68,"populationRelevance":78},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1007/s40279-026-02437-0","pmid":"41966639","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"2071e54257106d81d5a5427cc2725da9","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"The World Anti-Doping Code International Standard: Prohibited List","sourceUrl":"https://www.wada-ama.org/en/prohibited-list","evidenceTier":"insufficient","summary":"Official international sport source used to classify growth-hormone fragments and related substances in anti-doping rules.","authors":"World Anti-Doping Agency","publishingOrg":null,"publicationYear":2026,"doi":null,"pubmedId":null,"jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes regulatory evidence concerning The World Anti-Doping Code International Standard: Prohibited List","supportNature":"contextualizes","qualification":"Anti-doping status is not a determination of medical approval, clinical efficacy, or general legal status.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"url:https://www.wada-ama.org/en/prohibited-list","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"World Anti-Doping Agency","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"regulatory","extractionPayload":{"limitations":["Anti-doping status is not a determination of medical approval, clinical efficacy, or general legal status."],"studyDesign":"Official international anti-doping standard","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B+","score":82,"version":"WPF-ESR-1.0","dimensions":{"authority":96,"reporting":88,"directness":82,"replication":65,"designAndBias":78,"populationRelevance":65},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"regulatory_context"},"provenancePayload":{"doi":null,"pmid":null,"retrievedFrom":"World Anti-Doping Agency"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"2c3a925d671224e08a04a209896581ae","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42395176/","evidenceTier":"laboratory","summary":"Performance-enhancing drugs (PEDs) marketed as \"research compounds\" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis. The agents most commonly encountered in clinical practice and online self-ad …","authors":"Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M.","publishingOrg":null,"publicationYear":2026,"doi":"10.3389/fendo.2026.1822475","pubmedId":"42395176","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.","supportNature":"contextualizes","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.3389/fendo.2026.1822475","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"D","score":49,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":45,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"provenancePayload":{"doi":"10.3389/fendo.2026.1822475","pmid":"42395176","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"4c5ef150fb2d950370a5039f9b593dd9","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41490200/","evidenceTier":"laboratory","summary":"Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD- …","authors":"Rahman OF, Lee SJ, Seeds WA.","publishingOrg":null,"publicationYear":2026,"doi":"10.5435/JAAOSGlobal-D-25-00236","pubmedId":"41490200","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.","supportNature":"contextualizes","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.5435/jaaosglobal-d-25-00236","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"D","score":49,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":45,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"provenancePayload":{"doi":"10.5435/JAAOSGlobal-D-25-00236","pmid":"41490200","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"bde6582c53a0bbd81f85afa6dfe734db","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/35783198/","evidenceTier":"laboratory","summary":"OBJECTIVE: To evaluate the anticancer efficacy of Chitosan nanoparticles loaded with human growth hormone hGH fragment 176-191 peptide plus the clinical chemotherapeutic doxorubicin in comparison with Chitosan loaded with doxorubicin alone. METH …","authors":"Habibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, Bantun F, Alhazmi A, Hakamy A, Kaabi YA, Samlan G, Lohani M, Thangavel N, Al-Kasim MA.","publishingOrg":null,"publicationYear":2022,"doi":"10.2147/DDDT.S367586","pubmedId":"35783198","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.2147/dddt.s367586","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.2147/DDDT.S367586","pmid":"35783198","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"5c992bf7b3be86ba953518c8479a08e4","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/26578461/","evidenceTier":"laboratory","summary":"Several peptides <2 kDa with performance-enhancing properties are covered by the list of prohibited substances of the World Anti-Doping Agency including Desmopressin, LH-RH, Buserelin, Triptorelin, Leuprolide, GHRP-1, GHRP-2, GHRP-3, GHRP-4, GHRP-5,GHRP-6, Alexamorelin, Ipamor …","authors":"Thomas A, Görgens C, Guddat S, Thieme D, Dellanna F, Schänzer W, Thevis M.","publishingOrg":null,"publicationYear":2016,"doi":"10.1002/jssc.201501060","pubmedId":"26578461","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.","supportNature":"contextualizes","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/jssc.201501060","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"D","score":49,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":45,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"provenancePayload":{"doi":"10.1002/jssc.201501060","pmid":"26578461","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"f6bca61f48bf5e927921b3cf7ab3e022","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Detection and in vitro metabolism of AOD9604.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/25208511/","evidenceTier":"laboratory","summary":"AOD9604 is a peptide consisting of the C-terminal fragment of human growth hormone from amino acids 177-191 with an additional tyrosine residue at the N-terminus of the peptide. It is reported to mimic the lipolytic properties of growth hormone …","authors":"Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D.","publishingOrg":null,"publicationYear":2015,"doi":"10.1002/dta.1715","pubmedId":"25208511","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes in_vitro evidence concerning Detection and in vitro metabolism of AOD9604.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/dta.1715","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"in_vitro","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"In-vitro study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":58,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":18},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1002/dta.1715","pmid":"25208511","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"54cd239b4ad612c75aa34c0753cefd07","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/26275694/","evidenceTier":"animal","summary":"Weekly injections of 0.6 mL saline (Group 1), 6 mg HA (Group 2), 0.25 mg AOD9604 (Group 3), and 0.25 mg AOD9604 with 6 mg HA (Group 4) were administered for 4-7 weeks after the first intra-articular collagenase injection. ...The lameness period in Group 1 was signif …","authors":"Kwon DR, Park GY.","publishingOrg":null,"publicationYear":2015,"doi":null,"pubmedId":"26275694","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes animal_in_vivo evidence concerning Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"pmid:26275694","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"animal_in_vivo","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Animal in-vivo study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":46,"populationRelevance":25},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":null,"pmid":"26275694","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"6ebbe3904d1fda6184a79cad337a5a9d","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/24906629/","evidenceTier":"laboratory","summary":"Among these compounds, low- and high-molecular mass substances of peptidic (e.g. modified insulin-like growth factor-1, TB-500, hematide/peginesatide, growth hormone releasing peptides, AOD-9604, etc.) and non-peptidic (selective androgen recept …","authors":"Thevis M, Schänzer W.","publishingOrg":null,"publicationYear":2014,"doi":"10.1016/j.jpba.2014.05.020","pubmedId":"24906629","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.jpba.2014.05.020","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1016/j.jpba.2014.05.020","pmid":"24906629","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"6b0c4ec48c102337373675a919609138","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/25382550/","evidenceTier":"laboratory","summary":"These allow detecting the misuse of peptidic compounds of lower (such as growth hormone-releasing peptides, ARA-290, TB-500, AOD-9604, CJC-1295, desmopressin, luteinizing hormone-releasing hormones, synacthen, etc.), intermediate (e.g., insulins …","authors":"Thevis M, Thomas A, Schänzer W.","publishingOrg":null,"publicationYear":2014,"doi":"10.1586/14789450.2014.965159","pubmedId":"25382550","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1586/14789450.2014.965159","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1586/14789450.2014.965159","pmid":"25382550","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"8747040aad00cfe93e8fa1729ecb5448","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/24976118/","evidenceTier":"case_report","summary":"This peer-reviewed source examines Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604.","authors":"Vanhee C, Moens G, Deconinck E, De Beer JO.","publishingOrg":null,"publicationYear":2014,"doi":"10.1002/dta.1687","pubmedId":"24976118","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes case_report evidence concerning Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/dta.1687","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"case_report","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Case report or case series","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":62,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":34,"populationRelevance":58},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1002/dta.1687","pmid":"24976118","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"6a87e1fd7b58bbe46d3769d2f0a275cc","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"AOD-9604 does not influence the WADA hGH isoform immunoassay.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/24124033/","evidenceTier":"laboratory","summary":"This peer-reviewed source examines AOD-9604 does not influence the WADA hGH isoform immunoassay.","authors":"Orlovius AK, Thomas A, Schänzer W, Thevis M.","publishingOrg":null,"publicationYear":2013,"doi":"10.1002/dta.1557","pubmedId":"24124033","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning AOD-9604 does not influence the WADA hGH isoform immunoassay.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1002/dta.1557","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1002/dta.1557","pmid":"24124033","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"ea7882ab8747120186994d002ce01f33","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Current updates in the medical management of obesity.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/22435392/","evidenceTier":"laboratory","summary":"In this review, we discuss the FDA approved anti-obesity drugs and recent patents which include phentermine/topiramate, pramlintide, lorcaserin, AOD9604, oleoyl-estrone, trk-beta antagonists and melanin concentrating hormone that can reduce adiposity at the molecula …","authors":"Khan A, Raza S, Khan Y, Aksoy T, Khan M, Weinberger Y, Goldman J.","publishingOrg":null,"publicationYear":2012,"doi":"10.2174/187221412800604644","pubmedId":"22435392","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Current updates in the medical management of obesity.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.2174/187221412800604644","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":63,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":72,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.2174/187221412800604644","pmid":"22435392","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"f6dffc266949dc324756cbe6917174d4","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/17971763/","evidenceTier":"laboratory","summary":"The new antiobesity drugs under clinical development include: 1) agents that affect neurotransmitters in the central nervous system, including noradrenaline and dopamine reuptake inhibitors (bupropion, radafaxine), selective 5HT2C receptor agonists (lorcaserin), and selective 5HT …","authors":"Zieba R.","publishingOrg":null,"publicationYear":2007,"doi":null,"pubmedId":"17971763","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].","supportNature":"contextualizes","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"pmid:17971763","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":52,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":45,"replication":72,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"provenancePayload":{"doi":null,"pmid":"17971763","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"1c2bd3ed0ccfa98364ae6e2e524e28a3","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Obesity drugs in clinical development.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/16625817/","evidenceTier":"laboratory","summary":"These include: (i) centrally-acting drugs, such as the noradrenergic and dopaminergic reuptake inhibitor radafaxine, the endocannabinoid antagonist rimonabant, the selective serotonin 5-HT2c agonist APD-356, and oleoyl-estrone; (ii) drugs that target peripheral episodic satiety s …","authors":"Halford JC.","publishingOrg":null,"publicationYear":2006,"doi":null,"pubmedId":"16625817","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes mechanistic evidence concerning Obesity drugs in clinical development.","supportNature":"contextualizes","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"pmid:16625817","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"mechanistic","extractionPayload":{"limitations":["Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound."],"studyDesign":"Mechanistic or contextual peer-reviewed report","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"D","score":49,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":45,"replication":45,"designAndBias":42,"populationRelevance":30},"provisional":true},"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"provenancePayload":{"doi":null,"pmid":"16625817","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"79b6ecd9dd298653613d53e1e0470c43","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/16931496/","evidenceTier":"phase_1_2","summary":"Drugs that improve adipose tissue function or fatty acid metabolism (e.g., AOD9604) also are in clinical trials. Some currently available medications may reduce metabolic complications without treating obesity per se (e.g., acipimox, pioglitazone). ...","authors":"Jensen MD.","publishingOrg":null,"publicationYear":2006,"doi":"10.1038/oby.2006.294","pubmedId":"16931496","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes human_interventional evidence concerning Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.","supportNature":"contextualizes","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1038/oby.2006.294","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"human_interventional","extractionPayload":{"limitations":["Compound-specific human evidence remains limited in size, duration, outcomes, or replication."],"studyDesign":"Human interventional or clinical study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B","score":74,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":68,"populationRelevance":78},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1038/oby.2006.294","pmid":"16931496","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"3872fce72ac584ef6624297b7fed6a97","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Gateways to clinical trials.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/15834452/","evidenceTier":"phase_1_2","summary":"This issue focuses on the following selection of drugs: ABX-IL-8, Acclaim, adalimumab, AGI-1067, alagebrium chloride, alemtuzumab, Alequel, Androgel, anti-IL-12 MAb, AOD-9604, aripiprazole, atomoxetine hydrochloride; Biphasic insulin aspart, bosentan, botulinum toxi …","authors":"Bayés M, Rabasseda X, Prous JR.","publishingOrg":null,"publicationYear":2005,"doi":null,"pubmedId":"15834452","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes human_interventional evidence concerning Gateways to clinical trials.","supportNature":"contextualizes","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"pmid:15834452","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"human_interventional","extractionPayload":{"limitations":["Compound-specific human evidence remains limited in size, duration, outcomes, or replication."],"studyDesign":"Human interventional or clinical study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B","score":74,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":68,"populationRelevance":78},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":null,"pmid":"15834452","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"dfcad4cde56dad74d9d38426b3e53bd5","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"AOD-9604 Metabolic.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/15134286/","evidenceTier":"phase_1_2","summary":"Metabolic is developing AOD-9604 for the potential treatment of obesity. By February 2002, phase IIa trials were underway....","authors":"Wilding J.","publishingOrg":null,"publicationYear":2004,"doi":null,"pubmedId":"15134286","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes human_interventional evidence concerning AOD-9604 Metabolic.","supportNature":"contextualizes","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"pmid:15134286","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"human_interventional","extractionPayload":{"limitations":["Compound-specific human evidence remains limited in size, duration, outcomes, or replication."],"studyDesign":"Human interventional or clinical study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B","score":74,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":68,"populationRelevance":78},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":null,"pmid":"15134286","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"672f8bb2c5b6ef48456e163e4c783eb0","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Gateways to clinical trials.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/14685303/","evidenceTier":"phase_1_2","summary":"This issue focuses on the following selection of drugs: Abarelix, ABX-EGF, ademetionine, agomelatine, AMGN-0007, 9-aminocamptothecin, AN-9, anecortave acetate, anidulafungin, AOD-9604, apolizumab, apomate, L-arginine hydrochloride, arzoxifene hydrochloride; Bevacizu …","authors":"Bayes M, Rabasseda X, Prous JR.","publishingOrg":null,"publicationYear":2003,"doi":null,"pubmedId":"14685303","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes human_interventional evidence concerning Gateways to clinical trials.","supportNature":"contextualizes","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"pmid:14685303","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"human_interventional","extractionPayload":{"limitations":["Compound-specific human evidence remains limited in size, duration, outcomes, or replication."],"studyDesign":"Human interventional or clinical study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B","score":74,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":68,"populationRelevance":78},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":null,"pmid":"14685303","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"e8678b6770e9b2b2226e754b3ba30981","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Gateways to clinical trials.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/14571286/","evidenceTier":"phase_1_2","summary":"This issue focuses on the following selection of drugs: Abetimus sodium, adefovir dipivoxil, AGI-1067, alefacept, alemtuzumab, ALVAC-p53, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, Anti-CTLA-4 Mab, AOD-9604, apafant, aprinocarsen sodium, ar …","authors":"Bayés M, Rabasseda X, Prous JR.","publishingOrg":null,"publicationYear":2003,"doi":null,"pubmedId":"14571286","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes human_interventional evidence concerning Gateways to clinical trials.","supportNature":"contextualizes","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"pmid:14571286","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"human_interventional","extractionPayload":{"limitations":["Compound-specific human evidence remains limited in size, duration, outcomes, or replication."],"studyDesign":"Human interventional or clinical study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"B","score":74,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":68,"populationRelevance":78},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":null,"pmid":"14571286","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"e55a665ced8fdb1c51dcca910bac0a89","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/11673763/","evidenceTier":"animal","summary":"OBJECTIVE: To observe the chronic effects of human growth hormone (hGH) and AOD9604 (a C-terminal fragment of hGH) on body weight, energy balance, and substrate oxidation rates in obese (ob/ob) and lean C57BL/6Jmice. ...CONCLUSIONS: Both hGH and its C-termina …","authors":"Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM.","publishingOrg":null,"publicationYear":2001,"doi":"10.1038/sj.ijo.0801740","pubmedId":"11673763","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes animal_in_vivo evidence concerning Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1038/sj.ijo.0801740","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"animal_in_vivo","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Animal in-vivo study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":46,"populationRelevance":25},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1038/sj.ijo.0801740","pmid":"11673763","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"8a0661da6d666e5e2fd5a99a2345c39e","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/11713213/","evidenceTier":"animal","summary":"Both human GH (hGH) and a lipolytic fragment (AOD9604) synthesized from its C-terminus are capable of inducing weight loss and increasing lipolytic sensitivity following long-term treatment in mice. ...However, in an acute experiment, AOD9604 was capab …","authors":"Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM.","publishingOrg":null,"publicationYear":2001,"doi":"10.1210/endo.142.12.8522","pubmedId":"11713213","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes animal_in_vivo evidence concerning The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/endo.142.12.8522","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"animal_in_vivo","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Animal in-vivo study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":46,"populationRelevance":25},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1210/endo.142.12.8522","pmid":"11713213","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"30556739f21386a3161780585a2f3194","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","title":"Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/11146367/","evidenceTier":"animal","summary":"A synthetic analogue (AOD9604) of the lipolytic domain of human growth hormone (hGH) has been studied for its metabolic actions in obese Zucker rats. ...The adipose tissues of the AOD9604--treated animals were found to have an increase in lipolytic act …","authors":"Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R.","publishingOrg":null,"publicationYear":2000,"doi":"10.1159/000053183","pubmedId":"11146367","jurisdiction":null,"dateAccessed":"2026-09-08T19:33:45.384Z","editorialNotes":"AI-assisted corpus expansion authorized by owner on 2026-09-08. Relationship to named compound is explicitly classified.","sourceType":"peer_reviewed_research","claimSupported":"This source contributes animal_in_vivo evidence concerning Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.","supportNature":"contextualizes","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-eight-corpus-expansion-2026-09-08","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1159/000053183","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":"2026-09-08T19:33:45.384Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"wpf:aod-9604:wave2:2026-09-08","evidenceLane":"animal_in_vivo","extractionPayload":{"limitations":["Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety."],"studyDesign":"Animal in-vivo study","sourceStrength":{"note":"Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.","grade":"C","score":60,"version":"WPF-ESR-1.0","dimensions":{"authority":78,"reporting":68,"directness":88,"replication":45,"designAndBias":46,"populationRelevance":25},"provisional":true},"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"provenancePayload":{"doi":"10.1159/000053183","pmid":"11146367","retrievedFrom":"NCBI PubMed"},"validationGates":{"sourceVerified":true,"ownerAuthorized":true,"identityResolved":true,"relationshipClassified":true,"neutralLanguageVerified":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"}],"regulatory":[{"id":"f1b2f0e25d4a30f0df0caa489ba30e27","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","jurisdiction":"European Union (EMA)","status":"not_approved","approvedIndication":"No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.","rationale":"This is a time-bounded review of central EU authorization and does not replace member-state, clinical-trial, pharmacy-compounding, or sports-regulation analysis.","sourceTitle":"European Medicines Agency medicines database","sourceUrl":"https://www.ema.europa.eu/en/medicines","dateChecked":"2026-09-08T19:33:45.384Z","reviewDueAt":"2026-12-07T19:33:45.384Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"},{"id":"d944044b03ad5377f07b3b6a4dd3d310","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","jurisdiction":"United States (FDA)","status":"not_approved","approvedIndication":"No FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.","rationale":"This is a time-bounded database review, not a conclusion about efficacy, safety, compounding law, or approval in another jurisdiction.","sourceTitle":"Drugs@FDA: FDA-Approved Drugs","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","dateChecked":"2026-09-08T19:33:45.384Z","reviewDueAt":"2026-12-07T19:33:45.384Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z"}],"claims":[{"id":"79f62c87cffa92ba8b0778cbaa0e458f","claimKey":"aod-9604:source:9aca6c548468fc66b25b5461279576be","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes regulatory evidence concerning Drugs@FDA: FDA-Approved Drugs database","scope":{"evidenceLane":"regulatory","qualification":"Absence of an approved product does not itself establish efficacy or safety; database status can change.","sourceStrengthGrade":"B+","sourceStrengthScore":84,"directCompoundEvidence":true,"relationshipToNamedCompound":"regulatory_context"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"888a48b10fc1233f9c635b872568c65a","claimId":"79f62c87cffa92ba8b0778cbaa0e458f","evidenceId":"d977ce4ff2c8a161d425f07ff4c98d2b","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"https://www.accessdata.fda.gov/scripts/cder/daf/","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"dec626dd717db898048e74bcb02637c6","claimKey":"aod-9604:source:41490200","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes mechanistic evidence concerning Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.","scope":{"evidenceLane":"mechanistic","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","sourceStrengthGrade":"D","sourceStrengthScore":49,"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"9a61e68ec7de4d7a6b12a6ef62e12339","claimId":"dec626dd717db898048e74bcb02637c6","evidenceId":"4c5ef150fb2d950370a5039f9b593dd9","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 41490200","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"660fdc82aad5466830f68ad4c7d29a3e","claimKey":"aod-9604:source:41966639","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes human_interventional evidence concerning Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.","scope":{"evidenceLane":"human_interventional","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","sourceStrengthGrade":"B","sourceStrengthScore":74,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"762775123dc696448fab09cd54497893","claimId":"660fdc82aad5466830f68ad4c7d29a3e","evidenceId":"1ff7574acaeab39beb9ac62b31864cb6","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 41966639","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"fdbefc4cf4b6eafd403eb88ea53bdeac","claimKey":"aod-9604:source:15134286","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes human_interventional evidence concerning AOD-9604 Metabolic.","scope":{"evidenceLane":"human_interventional","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","sourceStrengthGrade":"B","sourceStrengthScore":74,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"bf1068f9048ba2b5a3388691cd55cdc3","claimId":"fdbefc4cf4b6eafd403eb88ea53bdeac","evidenceId":"dfcad4cde56dad74d9d38426b3e53bd5","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 15134286","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"05cee1c83157bb9833512a1f28442dce","claimKey":"aod-9604:source:35783198","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes mechanistic evidence concerning Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"8f689e77fe29ad635fc7bb10fa157b70","claimId":"05cee1c83157bb9833512a1f28442dce","evidenceId":"bde6582c53a0bbd81f85afa6dfe734db","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 35783198","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"0e41f200cd7ae8dfb2c1e9fd6724d5ba","claimKey":"aod-9604:source:25208511","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes in_vitro evidence concerning Detection and in vitro metabolism of AOD9604.","scope":{"evidenceLane":"in_vitro","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":58,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"62a33bece2161bac5a8de336fea2e90b","claimId":"0e41f200cd7ae8dfb2c1e9fd6724d5ba","evidenceId":"f6bca61f48bf5e927921b3cf7ab3e022","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 25208511","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"5c1a56cca29f1bfdcb4999bf29a02892","claimKey":"aod-9604:source:22435392","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes mechanistic evidence concerning Current updates in the medical management of obesity.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":63,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"60b566de8ec2267e26d556f7cc01401e","claimId":"5c1a56cca29f1bfdcb4999bf29a02892","evidenceId":"ea7882ab8747120186994d002ce01f33","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 22435392","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"b9658ed655ae0c09b1fb911b5a206576","claimKey":"aod-9604:source:16931496","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes human_interventional evidence concerning Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.","scope":{"evidenceLane":"human_interventional","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","sourceStrengthGrade":"B","sourceStrengthScore":74,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"c6d9f8fe8b7bb91d5ce632f42fe9e5f3","claimId":"b9658ed655ae0c09b1fb911b5a206576","evidenceId":"79b6ecd9dd298653613d53e1e0470c43","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 16931496","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"2e318f10d2189d81ad14c86d3ba21454","claimKey":"aod-9604:source:11713213","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes animal_in_vivo evidence concerning The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.","scope":{"evidenceLane":"animal_in_vivo","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"b34749299571edbf73bbd319c12903ec","claimId":"2e318f10d2189d81ad14c86d3ba21454","evidenceId":"8a0661da6d666e5e2fd5a99a2345c39e","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 11713213","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"fee65b897d6a9cadb9c45b93fa8c1800","claimKey":"aod-9604:source:14685303","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes human_interventional evidence concerning Gateways to clinical trials.","scope":{"evidenceLane":"human_interventional","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","sourceStrengthGrade":"B","sourceStrengthScore":74,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"e84cc2570bd28b9cc98db687f011e4d0","claimId":"fee65b897d6a9cadb9c45b93fa8c1800","evidenceId":"672f8bb2c5b6ef48456e163e4c783eb0","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 14685303","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"1512c5f9cc141d4dc61c4afa88c9fd01","claimKey":"aod-9604:source:14571286","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes human_interventional evidence concerning Gateways to clinical trials.","scope":{"evidenceLane":"human_interventional","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","sourceStrengthGrade":"B","sourceStrengthScore":74,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"77845e38e5b936031c4298c8c11b3506","claimId":"1512c5f9cc141d4dc61c4afa88c9fd01","evidenceId":"e8678b6770e9b2b2226e754b3ba30981","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 14571286","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"c9a7ef578d4fe7b24768305a14318066","claimKey":"aod-9604:source:15834452","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes human_interventional evidence concerning Gateways to clinical trials.","scope":{"evidenceLane":"human_interventional","qualification":"Compound-specific human evidence remains limited in size, duration, outcomes, or replication.","sourceStrengthGrade":"B","sourceStrengthScore":74,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"fa339814d94fba6d949f12ceb013b6b3","claimId":"c9a7ef578d4fe7b24768305a14318066","evidenceId":"3872fce72ac584ef6624297b7fed6a97","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 15834452","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"85b873ff32757d01edb91870428f2de1","claimKey":"aod-9604:source:11146367","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes animal_in_vivo evidence concerning Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.","scope":{"evidenceLane":"animal_in_vivo","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"af52cd200003db810f8078d62e028bcb","claimId":"85b873ff32757d01edb91870428f2de1","evidenceId":"30556739f21386a3161780585a2f3194","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 11146367","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"393f0f4ed070620e98fbd49088ec5424","claimKey":"aod-9604:source:25382550","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes mechanistic evidence concerning Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"b7c185748a68c902a934448bb8bd3a3b","claimId":"393f0f4ed070620e98fbd49088ec5424","evidenceId":"6b0c4ec48c102337373675a919609138","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 25382550","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"35a022a25011889c468f8beab52f248f","claimKey":"aod-9604:source:26275694","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes animal_in_vivo evidence concerning Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.","scope":{"evidenceLane":"animal_in_vivo","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"fa80dcd8a7c244a077c9a9764ac3ce7b","claimId":"35a022a25011889c468f8beab52f248f","evidenceId":"54cd239b4ad612c75aa34c0753cefd07","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 26275694","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"e3f9d8a790da26bd0e86ced3bdde5182","claimKey":"aod-9604:source:11673763","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes animal_in_vivo evidence concerning Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.","scope":{"evidenceLane":"animal_in_vivo","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"1f975ef54853ec3014a2446effcbba23","claimId":"e3f9d8a790da26bd0e86ced3bdde5182","evidenceId":"e55a665ced8fdb1c51dcca910bac0a89","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 11673763","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"7af968c1649d2509be54380fd09db59d","claimKey":"aod-9604:source:26578461","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes mechanistic evidence concerning Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.","scope":{"evidenceLane":"mechanistic","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","sourceStrengthGrade":"D","sourceStrengthScore":49,"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"6f12700cbafa7374ae849dcbc8c76e47","claimId":"7af968c1649d2509be54380fd09db59d","evidenceId":"5c992bf7b3be86ba953518c8479a08e4","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 26578461","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"ceb97bc6c5407dcfaa50d58e05376f98","claimKey":"aod-9604:source:16625817","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes mechanistic evidence concerning Obesity drugs in clinical development.","scope":{"evidenceLane":"mechanistic","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","sourceStrengthGrade":"D","sourceStrengthScore":49,"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"8c01f87dd83347de58eceafed7366ed9","claimId":"ceb97bc6c5407dcfaa50d58e05376f98","evidenceId":"1c2bd3ed0ccfa98364ae6e2e524e28a3","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 16625817","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"02944bc893477093e545cf40375cd28b","claimKey":"aod-9604:source:24976118","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes case_report evidence concerning Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604.","scope":{"evidenceLane":"case_report","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":62,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"31807e410a71dee97cccabe69c6c7753","claimId":"02944bc893477093e545cf40375cd28b","evidenceId":"8747040aad00cfe93e8fa1729ecb5448","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 24976118","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"0f7c319d2cf55f42025ad9087b1582da","claimKey":"aod-9604:source:42395176","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes mechanistic evidence concerning The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.","scope":{"evidenceLane":"mechanistic","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","sourceStrengthGrade":"D","sourceStrengthScore":49,"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"6b9717b8e51cac0ad09170918dcad330","claimId":"0f7c319d2cf55f42025ad9087b1582da","evidenceId":"2c3a925d671224e08a04a209896581ae","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 42395176","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"53ec6ed7c1de2bf87ed6de3ca5f6eb7d","claimKey":"aod-9604:source:24124033","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes mechanistic evidence concerning AOD-9604 does not influence the WADA hGH isoform immunoassay.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"a976d98333de4c8730f9c16ea882b96b","claimId":"53ec6ed7c1de2bf87ed6de3ca5f6eb7d","evidenceId":"6a87e1fd7b58bbe46d3769d2f0a275cc","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 24124033","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"1c2083cf77b4a2f498c5637d5deefcbd","claimKey":"aod-9604:source:24906629","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes mechanistic evidence concerning Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"cf977ace9b3ed4f23e2cb7b57c13dd13","claimId":"1c2083cf77b4a2f498c5637d5deefcbd","evidenceId":"6ebbe3904d1fda6184a79cad337a5a9d","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 24906629","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"9890e7a67d820e34986dd56de1a53c15","claimKey":"aod-9604:source:17971763","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes mechanistic evidence concerning [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].","scope":{"evidenceLane":"mechanistic","qualification":"Context source concerns a parent peptide, related analog, pathway, detection method, or broader class and must not be treated as direct evidence for the named compound.","sourceStrengthGrade":"C","sourceStrengthScore":52,"directCompoundEvidence":false,"relationshipToNamedCompound":"parent_analog_pathway_or_regulatory_context"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"140d96fa851c9ee250467e57ae8e8a6b","claimId":"9890e7a67d820e34986dd56de1a53c15","evidenceId":"f6dffc266949dc324756cbe6917174d4","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 17971763","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"a03d23c7a80896f1ed421d317ccfe8d3","claimKey":"aod-9604:source:42328738","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes mechanistic evidence concerning Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.","scope":{"evidenceLane":"mechanistic","qualification":"Compound-specific evidence is preclinical, mechanistic, or otherwise insufficient to establish human clinical efficacy or safety.","sourceStrengthGrade":"C","sourceStrengthScore":60,"directCompoundEvidence":true,"relationshipToNamedCompound":"direct_compound"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"598b67e420cce0c882755b5733864d80","claimId":"a03d23c7a80896f1ed421d317ccfe8d3","evidenceId":"ae59a8f4e28521c918339e89f58ed4a6","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"PubMed PMID 42328738","createdAt":"2026-09-08T19:33:45.384Z"}]},{"id":"1654a6a947ad1a5509b52149934a772d","claimKey":"aod-9604:source:df0f13284210314a4706de56867a7c41","peptideId":"51db6cd8-c874-47cf-8593-f0a75ba4432a","claimText":"This source contributes regulatory evidence concerning The World Anti-Doping Code International Standard: Prohibited List","scope":{"evidenceLane":"regulatory","qualification":"Anti-doping status is not a determination of medical approval, clinical efficacy, or general legal status.","sourceStrengthGrade":"B+","sourceStrengthScore":82,"directCompoundEvidence":true,"relationshipToNamedCompound":"regulatory_context"},"createdAt":"2026-09-08T19:33:45.384Z","updatedAt":"2026-09-08T19:33:45.384Z","evidenceLinks":[{"id":"06591ae1054cd5ab6be30ea56b4b6f64","claimId":"1654a6a947ad1a5509b52149934a772d","evidenceId":"2071e54257106d81d5a5427cc2725da9","relation":"contextualizes","sourceExcerpt":null,"sourceLocator":"https://www.wada-ama.org/en/prohibited-list","createdAt":"2026-09-08T19:33:45.384Z"}]}],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}